Cerebromab is an investigational monoclonal antibody designed to target and neutralize specific proteins involved in neurodegenerative diseases, particularly Alzheimer's disease. Its mechanism aims to reduce neuroinflammation and protect neurons, potentially slowing disease progression. While still under research, it represents a promising approach in the development of therapies for cognitive impairments associated with neurodegeneration. Clinical trials are ongoing to assess its efficacy and safety.